A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy

Trial Profile

A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RADIATE
  • Sponsors Roche
  • Most Recent Events

    • 08 Jun 2017 Results assessing liver safety with long-term tocilizumab treatment for rheumatoid arthritis using pooled data (n= 4171) from five core phase 3 placebo-controlled studies (OPTION, TOWARD, LITHE, AMBITION, RADIATE), a clinical pharmacology study (NCT00365001), a phase 4 study (ADACTA) or long-term extension studies, published in the Arthritis and Rheumatology Journal.
    • 30 Oct 2013 Tolerability results from a pooled analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 Jun 2012 Patient reported outcome results published in Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top